Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor a and the vascular endothelial growth factor a receptors 1 and 2 and neuropilin 1 and 2

Retina

Volumn 32, Issue 8, 2012, Pages 1652-1663

  Kernt, Marcus ^a   Thiele, Sarah ^a   Neubauer, Aljoscha S ^a   Koenig, Susanna ^a   Hirneiss, Christoph ^a   Haritoglou, Christos ^a   Ulbig, Michael W ^a   Kampik, Anselm ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

age related macular degeneration; choroidal neovascularization; multikinase inhibitors; pazopanib; platelet derived growth factor; ranibizumab; sorafenib; vascular endothelial growth factor A

Indexed keywords

MESSENGER RNA; NEUROPILIN 1; NEUROPILIN 2; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; RANIBIZUMAB; SORAFENIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PIGMENT EPITHELIUM; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; WHITE LIGHT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZENESULFONATES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; LIGHT; MIDDLE AGED; NEUROPILIN-1; NEUROPILIN-2; NEUROPILINS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84865751223     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318240a558     Document Type: Article

References (66)

1. Algvere PV, Seregard S. Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmol Scand 2002;80:136-143. (Pubitemid 34406844)
2. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med 2000;342:483-492. (Pubitemid 30100237)
3. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-2617.
4. Aiello LP. Targeting intraocular neovascularization and edema-one drop at a time. N Engl J Med 2008;359:967-969.
5. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
7. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339. (Pubitemid 41073113)
8. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-1513. (Pubitemid 40393297)
9. Bukowski RM. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:635-645.
10. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-3140.
11. Diago T, Pulido JS, Molina JR, et al. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc 2008;83:231-234. (Pubitemid 351303111)
12. Kernt M, Staehler M, Stief C, et al. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol 2008;86:456-458.
13. Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 2010;15:539-547.
14. Takahashi K, Saishin Y, Saishin Y, et al. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 2009;127:494-499.
15. Kernt M, Liegl RG, Rueping J, et al. Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. Growth Factors 2010;28: 211-220.
16. Kernt M, Neubauer AS, Liegl RG, et al. Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PIGF. Br J Ophthalmol 2010;94:1533-1539.
17. Kernt M, Thiele S, Hirneiss C, Neubauer AS, Lackerbauer CA, Wolf A, Eibl KH, Haritoglou C, Ulbig MW, Kampik A. [Cytoprotective and antiangiogenic effects of the multikinase inhibitor sorafenib on human retinal pigmentepithelium]. Ophthalmologe 2011;108:445-451.
18. Ehrlich R, Harris A, Kheradiya NS, et al. Age-related macular degeneration and the aging eye. Clin Interv Aging 2008;3:473-482.
19. Kernt M, Neubauer AS, Liegl R, et al. Cytoprotective effects of a blue light-filtering intraocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression. J Cataract Refract Surg 2009;35:354-362.
20. Algvere PV, Marshall J, Seregard S. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand 2006;84:4-15. (Pubitemid 43337467)
21. Holz FG, Pauleikhoff D, Klein R, Bird AC. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol 2004;137:504-510. (Pubitemid 38328643)
22. Barishak YR. In vitro behaviour of the pigmented cells of the retina and uvea of the adult human eye. Acta Ophthalmol (Copenh) 1960;38:339-346.
23. Flood MT, Gouras P, Kjeldbye H. Growth characteristics and ultrastructure of human retinal pigment epithelium in vitro. Invest Ophthalmol Vis Sci 1980;19:1309-1320. (Pubitemid 11078429)
24. Nilsson SE, Sundelin SP, Wihlmark U, Brunk UT. Aging of cultured retinal pigment epithelial cells: oxidative reactions, lipofuscin formation and blue light damage. Doc Ophthalmol 2003;106:13-16. (Pubitemid 36355966)
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
26. Roth F, Bindewald A, Holz FG. Key pathophysiologic pathways in age-related macular disease. Graefes Arch Clin Exp Ophthalmol 2004;242:710-716. (Pubitemid 39242849)
27. Holz FG, Bellmann C, Margaritidis M, et al. Patterns of increased in vivo fundus autofluorescence in the junctional zone of geographic atrophy of the retinal pigment epithelium associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237:145-152. (Pubitemid 29137302)
28. Schutt F, Bergmann M, Holz FG, Kopitz J. Isolation of intact lysosomes from human RPE cells and effects of A2-E on the integrity of the lysosomal and other cellular membranes. Graefes Arch Clin Exp Ophthalmol 2002;240:983-988. (Pubitemid 36097659)
29. Freyberger H, Brocker M, Yakut H, et al. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes 2000;108:106-109. (Pubitemid 30234973)
30. Robbins SG, Mixon RN, Wilson DJ, et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 1994;35: 3649-3663. (Pubitemid 24337978)
31. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004;242:91-101. (Pubitemid 38208289)
32. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29. (Pubitemid 36207453)
33. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92: 10457-10461.
34. Spaide RF. Rationale for combination therapy in age-related macular degeneration. Retina 2009;29:S5-S7.
35. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008;49:4523-4527.
36. Marmor MF. Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 1999;97:239-249.
37. Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res 2007;85:762-771. (Pubitemid 350166363)
38. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999;14:223-232. (Pubitemid 30061165)
39. Barber AJ, Antonetti DA. Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest Ophthalmol Vis Sci 2003;44:5410-5416. (Pubitemid 37475417)
40. Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 2004;286: C1213-C1228. (Pubitemid 38649971)
41. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-212. (Pubitemid 30070735)
42. Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008;27:372-390.
43. Haines JL, Schnetz-Boutaud N, Schmidt S, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci 2006;47:329-335. (Pubitemid 46780832)
44. Miyamoto N, de Kozak Y, Jeanny JC, et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 2007;50:461-470.
45. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of bloodisland formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-66.
46. Kinose F, Roscilli G, Lamartina S, et al. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Mol Vis 2005;11:366-373. (Pubitemid 41358271)
47. Takahashi H, Tamaki Y, Ishii N, et al. Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo. Curr Eye Res 2008;33:1002-1010.
48. Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 2007;24:643-662.
49. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 2002;64:162-169. (Pubitemid 34713242)
50. Kolodkin AL, Levengood DV, Rowe EG, et al. Neuropilin is a semaphorin III receptor. Cell 1997;90:753-762. (Pubitemid 27357966)
51. Takahashi T, Fournier A, Nakamura F, et al. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 1999; 99:59-69. (Pubitemid 29468630)
52. Winberg ML, Noordermeer JN, Tamagnone L, et al. Plexin A is a neuronal semaphorin receptor that controls axon guidance. Cell 1998;95:903-916. (Pubitemid 29019043)
53. Gluzman-Poltorak Z, Cohen T, Shibuya M, Neufeld G. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem 2001;276:18688-18694.
54. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-745. (Pubitemid 28155313)
55. Lee P, Goishi K, Davidson AJ, et al. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc Natl Acad Sci USA 2002; 99:10470-10475.
56. Takashima S, Kitakaze M, Asakura M, et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci USA 2002;99:3657-3662. (Pubitemid 34252162)
57. Shen J, Samul R, Zimmer J, et al. Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularization. Mol Med 2004;10:12-18. (Pubitemid 39440316)
58. Soker S, Miao HQ, Nomi M, et al. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 2002;85: 357-368. (Pubitemid 34274903)
59. Lim JI, Spee C, Hangai M, et al. Neuropilin-1 expression by endothelial cells and retinal pigment epithelial cells in choroidal neovascular membranes. Am J Ophthalmol 2005;140: 1044-1050.
60. Zhou J, Cai B, Jang YP, et al. Mechanisms for the induction of HNE-MDA-and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res 2005;80:567-580. (Pubitemid 40387526)
61. Yanagi Y, Inoue Y, Iriyama A, Jang WD. Effects of yellow intraocular lenses on light-induced upregulation of vascular endothelial growth factor. J Cataract Refract Surg 2006;32: 1540-1544. (Pubitemid 44262467)
62. Kernt M, Hirneiss C, Neubauer AS, Lackerbauer CA, Eibl KH, Wolf A, Ulbig M, Kampik A. [Protective effect of blue lightabsorbing IOLs on the human retinal pigment epithelium]. Ophthalmologe. 2010;107:150-157.
63. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-340.
64. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036-2053. (Pubitemid 43825322)
65. Schlingemann RO, Oosterwijk E, Wesseling P, et al. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J Pathol 1996;179:436-442. (Pubitemid 26276116)
66. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835-870. (Pubitemid 36828927)